CryoLabs Partnership Target biotechnology labs and hospitals seeking advanced liquid biopsy solutions for early cancer detection. VisionGate’s LuCED test and Cell-CT platform offer a non-invasive sputum-based workflow that can complement existing screening programs and drive value in early detection initiatives.

Strategic Collaborations Leverage recent board appointments and collaborations with cancer centers to approach institutions involved in personalized medicine and clinical trial partnerships. Highlight opportunities to integrate Cell-CT based diagnostics into BRDG-SPAN aligned research programs and pilot studies.

Cancer Portfolio Position Cell-CT as a versatile platform capable of detecting multiple cancer biosignatures from liquid biopsies. Explore co-development or licensing discussions with larger diagnostic players seeking expansion of liquid biopsy capabilities beyond lung cancer.

Funding Signals Emphasize the company’s NIH BRDG-SPAN grant history and ongoing development funds to prospective researchers and grant-facing customers. Use grant alignment to unlock pilot programs and shared-risk ventures with academic medical centers.

Growth Leap With a lean team and measurable revenue, pursue partnerships with mid-to-large diagnostics companies for manufacturing, distribution, and commercialization support. Propose channel partnerships to scale LuCED adoption in aligned geographies and markets.